Vilanterol
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Relvar Ellipta | — | 2013-11-13 | europa.eu ↗ |
Trials 114 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 123 trials | ||||||
| Phase 1 | NCT02837380 | Sep → Nov 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01837316 | Oct 2013 → Aug 2014 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01894386 | Jul → Sep 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01899638 | May → Jul 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01691547 | Dec 2012 → Mar 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01711463 | Dec 2012 → Jun 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01571999 | Mar → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01577680 | Mar → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01521377 | Dec 2011 → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01213849 | Oct → Nov 2010 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01165125 | Jul → Aug 2010 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01209026 | Jun 2010 → Jan 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01286831 | May → Jul 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01299558 | May → Jul 2010 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00976144 | Jul → Sep 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00783003 | Nov 2008 → Feb 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00711126 | Oct → Dec 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00964249 | Sep → Dec 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00671216 | May → Jul 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00702910 | Apr → Oct 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00625196 | Feb → May 2008 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00463697 | Apr → Aug 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00469040 | Feb → Apr 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT03739294 | Feb 2019 → Dec 2020 | — | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03645434 | Oct 2018 → Aug 2019 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03002389 | Nov 2017 → Dec 2023 overdue | chronic obstructive pulmonary disease | University of Virginia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02712047 | Apr 2016 → Feb 2017 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02570165 | Nov 2015 → Jul 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02164539 | Jul 2014 → Jul 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01453023 | Oct 2011 → Jun 2012 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01287065 | Oct 2010 → Sep 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01039675 | Jan → Apr 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00980200 | Sep 2009 → Jan 2010 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00749411 | Nov 2008 → Feb 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00731822 | Aug 2008 → Feb 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00519376 | Aug → Nov 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00347139 | May 2006 → Jan 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00354874 | Jan → Jun 2005 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 355 trials | ||||||
| Phase 3 | NCT07223294 | Apr 2026 | respiratory system disorder | Sandoz | Withdrawn | No outcome recorded |
| Phase 3 | NCT04651777 | Aug 2022 → Aug 2023 overdue | asthma | Dr. Grace Parraga | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04536675 | Apr 2021 → Apr 2026 overdue | chronic obstructive pulmonary disease, non-small cell lung carcinoma | Samsung Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03376932 | Jan 2019 → Feb 2021 | asthma | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT03248128 | Oct 2017 → Mar 2022 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02924688 | Oct 2016 → Feb 2019 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02729051 | Jun 2016 → May 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02487498 | Jul 2015 → Sep 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02446418 | Jul 2015 → Jul 2017 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02301975 | Mar 2015 → Nov 2016 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02345161 | Jan 2015 → Apr 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02257385 | Oct 2014 → May 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01899742 | Sep 2014 → Jul 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02152605 | Sep 2014 → Mar 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02164513 | Jun 2014 → Jul 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02105974 | Apr 2014 → Jul 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02094937 | Mar 2014 → Aug 2015 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01879410 | Jun 2013 → Jan 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01822899 | Apr → Oct 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01817764 | Mar → Oct 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01777334 | Jan → Sep 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01706198 | Nov 2012 → Dec 2016 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01691885 | Nov 2012 → Jul 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01706328 | Oct 2012 → Jun 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01686633 | Sep 2012 → Oct 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01551758 | Mar 2012 → Nov 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01491802 | Jan 2012 → Sep 2014 | chronic obstructive pulmonary disease | Queen's University | Completed | No outcome recorded |
| Phase 3 | NCT01498653 | Jan 2012 → Feb 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01376388 | Aug 2011 → Dec 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01395888 | Jun 2011 → Aug 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01323621 | Mar 2011 → Jan 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01323634 | Mar → Dec 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01323660 | Mar 2011 → Jul 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01336608 | Mar 2011 → Nov 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01313637 | Mar 2011 → Mar 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01313650 | Mar 2011 → Apr 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01316900 | Mar 2011 → Apr 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01328444 | Mar 2011 → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01316913 | Mar 2011 → Apr 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01342913 | Feb → Oct 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01313676 | Jan 2011 → Jul 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01316887 | Jan 2011 → Jul 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01181895 | Sep 2010 → Aug 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01165138 | Aug 2010 → Oct 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01192191 | Aug 2010 → Jan 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01244984 | Jul 2010 → Jan 2012 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01134042 | Jun 2010 → Oct 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01147848 | Jun 2010 → Jul 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01086384 | Feb 2010 → Sep 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01072149 | Jan → Jul 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01054885 | Oct 2009 → Feb 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01018186 | Oct 2009 → May 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01053988 | Oct 2009 → Feb 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01017952 | Sep 2009 → Oct 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01009463 | Sep 2009 → Oct 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT07192016 | Mar 2026 → Sep 2027 expected | chronic obstructive pulmonary disease | Western University, Canada | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06372496 | Apr 2024 → Jul 2025 overdue | asthma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06571942 | Nov 2023 → Jan 2025 overdue | chronic obstructive pulmonary disease | National Institute of Respiratory Diseases, Mexico | Recruiting | No outcome recorded |
| Phase 4 | NCT04923347 | Jun 2023 → Mar 2024 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05535972 | Oct 2022 → Sep 2023 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05292053 | Jul 2022 → Sep 2024 | chronic obstructive pulmonary disease | Baylor Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT04522596 | May 2021 → Dec 2024 | chronic obstructive pulmonary disease, heart failure | Luis Puente Maestu | Unknown | No outcome recorded |
| Phase 4 | NCT03949842 | Jun 2019 → Nov 2022 | chronic obstructive pulmonary disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 4 | NCT03478696 | Jun 2018 → Mar 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03467425 | Apr 2018 → Oct 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03474081 | Mar 2018 → Jul 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03363191 | Mar 2018 → May 2019 | asthma | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 4 | NCT03315000 | Oct 2017 → May 2018 | asthma | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT03034915 | Jun 2017 → Jun 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02799784 | Jul 2016 → Apr 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02730351 | May 2016 → Feb 2017 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02275052 | Jan 2015 → Jun 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01957150 | Jan 2014 → Mar 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07541378 | Mar 2024 → Feb 2025 | chronic obstructive pulmonary disease | Medical University of Bialystok | Suspended | No outcome recorded |
| — | NCT06077019 | Oct 2023 → Jul 2026 overdue | — | Morten Hostrup, PhD | Recruiting | No outcome recorded |
| — | NCT06066606 | Oct 2023 → Jul 2026 overdue | — | Morten Hostrup, PhD | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 26 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02666287 Background | Jan → Jun 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT04072887 Background | Sep 2019 → Oct 2021 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01573624 Comparator | Apr 2012 → Feb 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01573767 Comparator | Apr 2012 → Apr 2014 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01453296 Comparator | Aug 2010 → Apr 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01128569 Comparator | Jan → Oct 2010 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00606684 Comparator | Feb → Oct 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00372112 Comparator | Nov 2006 → May 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT05757102 Background | Apr 2023 → Jan 2027 expected | asthma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT03162055 Comparator | May 2017 → May 2018 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02753712 Comparator | Jun 2016 → Aug 2017 | asthma | Mundipharma Research Limited | Completed | No outcome recorded |
| Phase 3 | NCT02731846 Background | Jun → Nov 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT02467452 Comparator | May 2015 → Jan 2017 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT01957163 Background | Oct 2013 → Apr 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02119286 Background | Oct 2013 → Apr 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01435902 Comparator | Jan → Aug 2012 | asthma | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT01498679 Comparator | Jan 2012 → Jul 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT06552364 Comparator | Apr 2025 → Dec 2026 expected | chronic obstructive pulmonary disease | University of British Columbia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07133880 Comparator | Dec 2023 → Dec 2025 overdue | chronic obstructive pulmonary disease | University of Tennessee Graduate School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT04671355 Comparator | Oct → Dec 2021 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Withdrawn | No outcome recorded |
| Phase 4 | NCT03611699 Comparator | Jan 2019 → Apr 2020 | chronic obstructive pulmonary disease | Gary L. Pierce | Completed | No outcome recorded |
| Phase 4 | NCT03380429 Background | Jan 2018 → Jan 2019 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05342558 Comparator | Sep 2017 → Nov 2020 | chronic obstructive pulmonary disease | National Institute of Respiratory Diseases, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT03152149 Comparator | Jun 2017 → Nov 2019 | chronic obstructive pulmonary disease | University of Dundee | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07329946 Background | Sep 2026 → Feb 2027 expected | chronic obstructive pulmonary disease | Pierachille Santus, MD, PhD | Not yet recruiting | No outcome recorded |
| — | NCT07058259 Background | Nov 2024 → Jun 2025 overdue | chronic obstructive pulmonary disease | Istanbul Medeniyet University | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 141 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vilanterol | “We present the protocol for the ongoing INTREPID (INvestigation of TRelegy Effectiveness: usual PractIce Design; ClinicalTrials.gov identifier: NCT03467425) study, a...” PMID 31720293 ↗ Nov 2019105“Participants will inhale a ultra Long-Acting Beta-Agonist (LABA; vilanterol (25mcg)) + Long-acting Muscarinic Antagonist (LAMA; umeclidinium (62.5mcg)) combination medication...” NCT06552364 ↗ “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled...” PMID 26006754 ↗ May 2015 “A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation...” NCT01706328 ↗ “A 12-week, Prospective, Open Label, Single Cohort Study to Evaluate the Real-world Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler...” NCT05535972 ↗ “Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol...” NCT03376932 ↗ “pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a...” PMID 31321713 ↗ Jan 2020 “OBJECTIVE: To evaluate the effect of the addition of a novel LABA, vilanterol (VI), to a once-daily ICS, fluticasone furoate (FF), on the risk of severe asthma exacerbations in...” PMID 24253831 ↗ Nov 2013 “A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic...” NCT03474081 ↗ “All subjects received fluticasone furoate/vilanterol ELLIPTA dry-powder inhalers for maintenance and salbutamol/albuterol metered-dose inhalers for rescue, with a sensor...” PMID 33334936 ↗ Jun 2021 “A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary...” NCT02275052 ↗ “Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.” NCT01957163 ↗ “Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.” NCT02119286 ↗ “A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)” NCT01551758 ↗ “Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.” PMID 25816315 ↗ Mar 2015 “Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.” PMID 29094315 ↗ Nov 2017 “Vilanterol, long-acting beta2-agonist (LABA). Administered as 22 μg, 1 inhalation once daily via Ellipta inhaler for 28 days in combination with umeclidinium.” NCT07541378 ↗ “Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®)” NCT02467452 ↗ “A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)” NCT02152605 ↗ “Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma” NCT03248128 ↗ “The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol.” NCT04651777 ↗ “long-acting muscarinic antagonist/β2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared with UMEC and VI monotherapies” PMID 23830094 ↗ Jul 2013 “Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.” NCT05757102 ↗ “second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate” NCT03034915 ↗ “inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days” NCT03002389 ↗ “TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)” NCT05292053 ↗ “two 1-year randomised, controlled trials of fluticasone furoate (FF)/vilanterol (VI) versus VI alone” PMID 27251682 ↗ Jun 2016 “fixed-dose combination bronchodilator (umeclidinium/vilanterol (UMEC/VI); 62.5 µg/25 µg)” PMID 34503985 ↗ Apr 2022 “Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.” PMID 24385182 ↗ May 2014 “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy” NCT03478696 ↗ “Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg])” NCT02837380 ↗ “combination fluticasone furoate (FF)/vilanterol (VI) in Asian asthma patients.” PMID 25524507 ↗ Oct 2014 “Vilanterol is available as vilanterol inhalation powder (25 mcg per blister)” NCT02164539 ↗ “second strip contains Vilanterol (unit dose strengths 25 mcg per blister)” NCT02257385 ↗ “Combination of fluticasone furoate, vilanterol and umeclidinium bromide” NCT04072887 ↗ “Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg Combination” NCT01837316 ↗ “once daily in case of umeclidinium bromide/vilanterol 55/22 mcg” NCT07329946 ↗ “Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI)” NCT04923347 ↗ “Vilanterol is a long-acting beta2 agonist (LABA).” NCT01691547 ↗ “the long-acting β2-agonist (LABA) vilanterol (VI)” PMID 33598874 ↗ Feb 2021 “umeclidinium (GSK573719) / vilanterol (GW642444)” NCT01491802 ↗ “or vilanterol 25 mcg (a long-acting β-agonist)” PMID 25452139 ↗ Oct 2014 “umeclidinium (UMEC) plus vilanterol (VI)” PMID 24835833 ↗ May 2014 “Vilanterol (VI)” NCT01894386 ↗ |
| Known as | GW642444 | “A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)” NCT01551758 ↗42“fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)” NCT01395888 ↗ “GSK573719 (500mcg) Inhalation Powder and GW642444 (25mcg) Inhalation Powder administered once-daily via a novel dry powder inhaler (Novel DPI)” NCT01039675 ↗ “selected doses and dose intervals of GW642444 Administered Via a Novel Dry Powder Inhaler (NDPI)” NCT00980200 ↗ “vilanterol (VI, GW642444) is an inhaled once daily long-acting beta2 agonist (LABA)” NCT01453023 ↗ “Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder” NCT02446418 ↗ “Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder” NCT01706198 ↗ “GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)” NCT01498679 ↗ “GW642444 is a potent and selective long-acting beta-2 agonist.” NCT00976144 ↗ “Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg” NCT01323634 ↗ “Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg” NCT01323621 ↗ “umeclidinium (GSK573719) / vilanterol (GW642444)” NCT01491802 ↗ |
| Known as | GW642444H | “Participants in this study will receive both the "H" salt (GW642444H) and the new "M" salt (GW642444M) containing magnesium stearate.” NCT00463697 ↗1“Participants in this study will receive both the 'H' salt (GW642444H) and the new 'M' salt (GW642444M) containing magnesium stearate.” NCT00519376 ↗ |
| Known as | GW642444M | “Participants in this study will receive both the "H" salt (GW642444H) and the new "M" salt (GW642444M) containing magnesium stearate.” NCT00463697 ↗3“Participants in this study will receive both the 'H' salt (GW642444H) and the new 'M' salt (GW642444M) containing magnesium stearate.” NCT00519376 ↗ “repeat dose GSK573719/GW642444M (Vilanterol) combination” NCT01521377 ↗ “FF/Vilanterol (VI; GW642444M)” NCT01128569 ↗ |
| Known as | vilanterol trifenatae | “second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate” NCT03034915 ↗ |
| Known as | vilanterol trifenatate | “GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)” NCT01498679 ↗ |
| Action | Activate | “long acting beta agonist GW642444” NCT00749411 ↗ |
| Modality | Other / unclassified | “The inhaled corticosteroid fluticasone furoate (FF) and the long-acting β₂ agonist vilanterol (VI) are in development as a combined once-daily therapy for asthma and chronic...” PMID 24136330 ↗ Oct 2013 |
| Route | Inhaled | “Three Inhaled Doses (25, 100 and 400 mcg Once Daily) of GW642444” NCT00347139 ↗ |